TCF4 and lung adenocarcinoma: The Wnt antagonist RUNX3 prevents the binding of the TCF4‐β‐catenin complex to target promoters and is responsible for the cell cycle and regulation of apoptosis. In lung adenocarcinoma, RUNX3 promoter hypermethylation is disrupted by the Wnt signaling pathway.